BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29664013)

  • 1. β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.
    Nsengimana J; Laye J; Filia A; O'Shea S; Muralidhar S; Poźniak J; Droop A; Chan M; Walker C; Parkinson L; Gascoyne J; Mell T; Polso M; Jewell R; Randerson-Moor J; Cook GP; Bishop DT; Newton-Bishop J
    J Clin Invest; 2018 May; 128(5):2048-2063. PubMed ID: 29664013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
    Min KW; Choe JY; Kwon MJ; Lee HK; Kang HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Kim YJ; Kim NY; Kim HY
    Pathol Res Pract; 2019 Dec; 215(12):152671. PubMed ID: 31630873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations.
    Tsushima N; Kano S; Hatanaka KC; Suzuki T; Hamada S; Idogawa H; Nakamaru Y; Suzuki M; Hatanaka Y; Homma A
    Auris Nasus Larynx; 2024 Apr; 51(2):313-319. PubMed ID: 37953090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of molecular alterations with immune response in melanoma.
    Szczepaniak Sloane RA; Gopalakrishnan V; Reddy SM; Zhang X; Reuben A; Wargo JA
    Cancer; 2017 Jun; 123(S11):2130-2142. PubMed ID: 28543700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
    Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
    PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk stratification of cutaneous melanoma reveals carcinogen metabolism enrichment and immune inhibition in high-risk patients.
    Li X; Cai Y
    Aging (Albany NY); 2020 Aug; 12(16):16457-16475. PubMed ID: 32858528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational profiling of acral melanomas in Korean populations.
    Shim JH; Shin HT; Park J; Park JH; Lee JH; Yang JM; Kim DH; Jang KT; Lee DY
    Exp Dermatol; 2017 Oct; 26(10):883-888. PubMed ID: 28191690
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.
    Jahn SW; Kashofer K; Halbwedl I; Winter G; El-Shabrawi-Caelen L; Mentzel T; Hoefler G; Liegl-Atzwanger B
    Mod Pathol; 2015 Jul; 28(7):895-903. PubMed ID: 25769001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
    Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
    Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
    Carlino MS; Haydu LE; Kakavand H; Menzies AM; Hamilton AL; Yu B; Ng CC; Cooper WA; Thompson JF; Kefford RF; O'Toole SA; Scolyer RA; Long GV
    Br J Cancer; 2014 Jul; 111(2):292-9. PubMed ID: 24918823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immune-related role of BRAF in melanoma.
    Tomei S; Bedognetti D; De Giorgi V; Sommariva M; Civini S; Reinboth J; Al Hashmi M; Ascierto ML; Liu Q; Ayotte BD; Worschech A; Uccellini L; Ascierto PA; Stroncek D; Palmieri G; Chouchane L; Wang E; Marincola FM
    Mol Oncol; 2015 Jan; 9(1):93-104. PubMed ID: 25174651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors.
    Chang GA; Wiggins JM; Corless BC; Syeda MM; Tadepalli JS; Blake S; Fleming N; Darvishian F; Pavlick A; Berman R; Shapiro R; Shao Y; Karlin-Neumann G; Spittle C; Osman I; Polsky D
    J Invest Dermatol; 2020 Aug; 140(8):1609-1618.e7. PubMed ID: 32087194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordance of somatic mutational profile in multiple primary melanomas.
    Adler NR; McLean CA; Wolfe R; Kelly JW; McArthur GA; Haydon A; Tra T; Cummings N; Mar VJ
    Pigment Cell Melanoma Res; 2018 Sep; 31(5):592-603. PubMed ID: 29603877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
    Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
    Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
    Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN
    Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.